Sanofi
Sanofi Accelerates Beyfortus Shipping Ahead of Next RSV Season
Sanofi said it would ship nirsevimab starting earlier to ensure broad availability well ahead of the 2025-2026 RSV ...
JUNE 9, 2025
Sanofi Ships U.S. Influenza Vaccines for 2024-2025 Season
In July, Sanofi began shipping its first influenza vaccines across the United States in preparation for the ...
JULY 11, 2024
ACIP Recommends Beyfortus to Prevent RSV in Infants
The CDC’s Advisory Committee on Immunization Practices voted unanimously for universal use of nirsevimab ...
AUGUST 3, 2023
Beyfortus Approved to Prevent RSV in Infants and Children
The FDA approved Beyfortus (Sanofi and AstraZeneca) for the prevention of RSV lower respiratory tract disease in ...
JULY 18, 2023
Altuviiio Highly Effective Against Bleeding in Children With Severe Hemophilia A
The phase 3 XTEND-Kids study evaluating antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, ...
JUNE 26, 2023
Sanofi and Roche Reach Tamiflu Deal
Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketing, ...
JULY 24, 2019
Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients
The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.
FEBRUARY 12, 2019
FDA Approves Cablivi, First Therapy to Treat aTTP
In the United States, acquired thrombotic thrombocytopenic purpura affects fewer than 2,000 adults each year.
FEBRUARY 7, 2019
FDA Advisory Committee Split Over Approval for Zynquista
FDA advisory committee was divided about whether the overall benefits of Zynquista to treat adults with type 1 ...
JANUARY 18, 2019
FDA Expands Use of Adacel Vaccine
The FDA granted the expanded use of Sanofi’s Adacel vaccine to include repeat vaccination to help protect ...
JANUARY 15, 2019
FDA Approves Vaxelis, a Pediatric Vaccine That Protects Against 6 Diseases
The FDA approved a new vaccine that allows children to be vaccinated against six diseases at once, so they will ...
DECEMBER 30, 2018
FDA Approves New Indication for Dupixent for Asthma
Dupilumab inhibits the overactive signaling of IL-4 and IL-13, two key proteins that contribute to the Type 2 ...
OCTOBER 20, 2018
